Constipation News and Research

Latest Constipation News and Research

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

FDA qualifies C-Path’s DIBSS-C for clinical trials

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA).

10 Mar 2021

Study finds increased opioid consumption two years after intensive care

Nearly 11 percent of people admitted to an intensive care unit in Sweden between 2010 and 2018 received opioid prescriptions on a regular basis for at least six months and up to two years after discharge.

2 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Researchers find potential biomarkers of Parkinson's disease

A research team led by Nagoya University in Japan has found that blood pressure, the hematocrit (the percentage of red blood cells in blood), and serum cholesterol levels change in patients with Parkinson's disease long before the onset of motor symptoms.

18 Jan 2021

Study sheds light on the causes of debilitating gut pain

A new study, published in the journal Nature, reports evidence from mice and humans that a novel mechanism contributes to chronic gut pain.

17 Jan 2021

C-Path PRO Consortium measure now included in FDA-approved label claim

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces that clinical study results using the Consortium's Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) were recently included in the expanded label for the drug LINZESS® (linaclotide).

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Study investigates the total non-healthcare cost of chemotherapy

Chemotherapy for breast cancer costs the UK economy more than £248 million annually, including 'out-of-pocket' personal costs of more than £1,000 per patient - according to new research from the University of East Anglia.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Today, the U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.

18 Dec 2020

Project explores how carers recognize and manage health deterioration in people with learning disabilities, autism

A research team at Northumbria University have launched a major project exploring how carers recognise and manage deterioration in the health of people with learning disabilities and autism.

18 Dec 2020

COVID-19 pandemic highlights the risk of using systemic corticosteroids

Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.

17 Dec 2020

Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study

Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal.

17 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Fan therapy may offer relief for patients with advanced cancer experiencing breathlessness

Blowing air from a fan into the face of patients with advanced cancer experiencing breathlessness, and other nonpharmacologic interventions, may offer symptom relief, according to new research directed by Johns Hopkins Kimmel Cancer Center investigators.

10 Dec 2020

Constipation News and Research

Latest Constipation News and Research

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

FDA qualifies C-Path’s DIBSS-C for clinical trials

Study finds increased opioid consumption two years after intensive care

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Researchers find potential biomarkers of Parkinson's disease

Study sheds light on the causes of debilitating gut pain

C-Path PRO Consortium measure now included in FDA-approved label claim

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Study investigates the total non-healthcare cost of chemotherapy

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Project explores how carers recognize and manage health deterioration in people with learning disabilities, autism

COVID-19 pandemic highlights the risk of using systemic corticosteroids

Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study

RedHill Biopharma announces promising preliminary results from opaganib study

Fan therapy may offer relief for patients with advanced cancer experiencing breathlessness

Bilayered delivery system offers new solution for treating IBS-C patients

OU Health Sciences Center receives federal grant for opioid management in older adults

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Constipation News and Research

Latest Constipation News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in